本报讯 （记者张敏）1月4日，记者从北京科兴控股（集团）有限公司（以下简称"科兴"）获悉，智利政府2026年度流感疫 苗全球招标结果近日揭晓，科兴再度成为独家供应商，签约订单超800万剂。首批疫苗将于2026年1月底前运抵智利，以满足智 利即将到来的流感季防护需求。科兴连续两年独家承担该国流感疫苗供应任务，标志着该公司产品质量与国际履约能力持续获 得智利公共卫生系统的认可。 科兴与智利多方伙伴的合作已从产品供应拓展至科研协同与证据共建。2024年8月，国际期刊《疫苗》（Vaccines）发表了 科兴与智利等国科研伙伴共同完成的四价流感疫苗国际多中心临床研究结果，科兴流感疫苗良好的免疫原性与安全性得到验 证，其诱导针对四种型别流感病毒的抗体滴度均高于国外对照疫苗。近日，另一项在智利成年人群中开展的同时评价体液与细 胞免疫应答的Ⅲ期研究也在《自然-通讯》（NatureCommunications）上发表，进一步揭示了科兴流感疫苗拥有良好免疫原性与 安全性的科学基础。 凭借可靠的品质与循证支持，科兴流感疫苗的全球应用持续扩展。截至目前，科兴流感疫苗已进入全球近20个国家和地 区，累计供应超1.2亿剂，持续为全球流感 ...

凭借可靠品质与循证支持，科兴流感疫苗的全球应用持续扩展。截至目前，疫苗已进入全球近20个 国家和地区，累计供应超1.2亿剂，持续为全球流感防控提供稳定助力。 编辑：孙庭阳 科兴与智利多方伙伴的合作已从产品供应拓展至科研协同与证据共建。2024年8月，国际期刊《疫 苗》（Vaccines）发表了科兴与智利等国科研伙伴共同完成的四价流感疫苗国际多中心临床研究结果， 科兴流感疫苗良好的免疫原性与安全性得到验证，其诱导针对四种型别流感病毒的抗体滴度均高于国外 对照疫苗。近日，另一项在智利成年人群中开展的同时评价体液与细胞免疫应答的Ⅲ期研究也在《自 然-通讯》（Nature Communications）上发表，进一步揭示了科兴流感疫苗拥有良好免疫原性与安全性 的科学基础。 智利政府2026年度流感疫苗全球招标结果近日揭晓，科兴再度成为独家供应商，签约订单超800万 剂。首批疫苗将于2026年1月底前运抵智利，满足智利的流感季防护需求。科兴连续两年独家承担智利 流感疫苗供应任务，标志着科兴产品质量与国际履约能力持续获得该国公共卫生系统的认可。 这个合作建立在科兴坚实的履约成效之上。2025年，由科兴独家供应的流感疫苗在 ...

Group 1 - The Shanghai Cooperation Organization (SCO) held its eighth health ministers' meeting in Xi'an, focusing on promoting sustainable health development and sharing a healthy future [1] - SCO member countries agreed to deepen cooperation in emergency medicine, primary health care, digital health, and traditional medicine [1] - Chinese vaccine company Sinovac has established a diverse cooperation system with multiple countries under the SCO framework, covering research, supply, and industrialization [1] Group 2 - Sinovac has supplied over 33 million doses of routine vaccines, including hepatitis A, flu, and varicella vaccines, to SCO member countries [1] - The hepatitis A vaccine from Sinovac is the preferred choice for immunization programs in several SCO countries, with over 10 million doses supplied to Uzbekistan, Kazakhstan, India, and Pakistan [1] - In Uzbekistan, Sinovac's hepatitis A vaccine achieved over 95% market share in the private sector, with a coverage rate exceeding 69% for children in 2024 [1] Group 3 - Sinovac's varicella vaccine received prequalification from the World Health Organization, and it was first supplied to Belarus in late 2023, addressing a shortage of varicella vaccines [1] - Sinovac's flu vaccine was launched in Pakistan in 2024 and quickly became a mainstream brand [2] - Sinovac donated 100,000 doses of inactivated hepatitis A vaccine to Pakistan during severe flooding in 2022, receiving appreciation from local health authorities [2] Group 4 - Sinovac is actively engaged in industrial cooperation with SCO partners, including establishing a vaccine factory in Turkey and building a large automated vaccine cold storage facility in Egypt [2] - The cold storage facility in Egypt is the largest vaccine storage center in Africa, covering an area of 2,800 square meters [2] - Sinovac has developed 12 vaccines over its 24 years of operation, gaining wide recognition globally [2]